Treatment options for Anal cancer mapped across 7 countries — covering cell therapy, chemotherapy, clinical trials and immunotherapy — each linking to its regulator, HTA, or guideline source, with questions to bring to your care team. Options, not recommendations.
Options mappedSolid tumorLast checked June 2026
Options by country
Treatments by country
Regulatory and access status by country, from official sources. It shows what exists and where — not a recommendation.
European Union
Retifanlimab (Zynyz) with carboplatin and paclitaxel[1]EMA authorisedNo biomarker requirement stated in fetched EMA news source; Adults with SCAC that cannot be removed by surgery and is metastatic or locally recurrent, in combination with carboplatin and paclitaxel. · The fetched EMA source is a recommendation/news page, not final EPAR product information; European Commission authorization status and member-state reimbursement must be verified separately. No claim is made for monotherapy EU use from this source. Confidence/conflicts: Medium-high for EMA CHMP recommendation; final authorization and country access remain follow-up gaps.
This is official regulatory and access status only — not medical advice, not a recommendation, and not a statement about eligibility. Whether any option fits depends on your situation and your oncology team. Status changes over time; confirm the current position with the linked source. Last checked June 2026.
Beyond approved care
In clinical trials & emerging options
Options that are not — or not yet — an approved standard where you live: studies, clinical trials, off-label use, and early evidence that your own oncologist may not raise. Each is labeled by how strong the evidence is. A listing here is information to research and discuss with your team; it does not mean a treatment is proven, safe for you, or available today.
Retifanlimab plus carboplatin/paclitaxel; KFA115 plus pembrolizumabClinical trial · NCT04472429Clinical trialTrial only (registry)Japan · No biomarker requirement stated for POD1UM-303 SCAC record; broad KFA115 study may have cohort-specific criteria; Locally advanced or metastatic SCAC; selected advanced cancer cohort including anal cancer. · Registry records do not establish PMDA approval, reimbursement, routine access, or individual eligibility. POD1UM-303 is completed; KFA115 is a broad phase 1 cohort. Confidence/conflicts: High for Japan registry-listed anal cancer activity; local approval/access unverified. ClinicalTrials.gov — clinical-trial registry
Vobramitamab duocarmazine; KFA115 plus pembrolizumab; BI 754091 alone or with BI 836880Clinical trial · NCT05551117Clinical trialTrial only (registry)Korea · No biomarker requirement stated in fetched Korea records; Advanced anal cancer cohort; advanced anal canal squamous cell carcinoma. · Registry records do not establish MFDS approval, reimbursement, routine access, or individual eligibility. Two selected Korea records are terminated or withdrawn, and broad cohort studies require confirmation of anal cancer-specific enrollment. Confidence/conflicts: Medium-high for Korea registry-listed activity; current access is limited/uncertain. ClinicalTrials.gov — clinical-trial registry
Stimotimagene copolymerplasmid plus ganciclovirClinical trial · NCT05578820Clinical trialTrial only (registry)Russia · No biomarker requirement stated in fetched Russia record; Broad tumor-type study including anus neoplasms. · Registry record does not establish Russian regulator approval, reimbursement, routine access, current availability, or anal cancer-specific enrollment at each site. Confidence/conflicts: Medium for Russia broad anus-neoplasm registry activity; anal cancer-specific access unverified. ClinicalTrials.gov — clinical-trial registry
A clinical-trial listing or early report shows an option is being studied — not that it works, that it is safe for any one person, or that a site is enrolling today. Whether any of these fits is a conversation for your oncology team and the trial team. Last checked June 2026.
What this page does
Maps options by country
It maps sourced options by country alongside diagnosis wording, stage, test results, specialists, and trial-search terms.
What it does not do
Does not choose treatment
It does not rank treatments, recommend a choice, or decide clinical fit.
Where it comes from
Built on trusted sources
Every option links to a trusted regulator, HTA, or guideline source, and the list grows as new sources pass verification.
Information to gather before the next visit
Is the diagnosis anal canal squamous cell carcinoma, perianal skin cancer, or another anal tumor subtype?
Is treatment being planned for localized disease, residual/recurrent disease, or metastatic/inoperable locally recurrent disease?
Is retifanlimab being considered first-line with chemotherapy or after platinum progression/intolerance?
Has the EMA recommendation been converted into local authorization and reimbursement in the treating country?